In recent years, the field of surgical oncology has witnessed the emerging use of novel therapeutic agents and treatment modalities as front-line regimens for many resectable malignant cancers in the neoadjuvant and adjuvant settings. Such paradigm shift has also been seen in bone and soft tissue sarcoma where novel targeted agents, immunotherapy and multimodal management are now being tested in the peri-operative scenarios. The benefit includes, exposing tumor neoantigen and immune infiltration to therapeutic agents, downstaging a sarcoma into resectable state, and eradicating micro-metastasis to improve survival. However, the optimal candidate, timing, strategy of such peri-operative regimens remains under-studied. The potential increase of peri-operative complication and adverse effect poses new challenges for physicians and surgeons. Therefore, the optimal combination and scientific rationales of these new therapeutics and regimens in the peri-operative setting of bone and soft tissue sarcoma needs to be further investigated.
This Research Topic aims to explore the potential benefit, risk and biomarkers of novel therapeutics and regimens, such as tyrosine-kinase inhibitor, immunotherapy, chemoradiation and intra-tumoral manipulation, in the peri-operative settings for resectable bone and soft tissue sarcoma. Correlative and translational investigation is also welcomed for the optimization of novel combination strategies, patient selection and the scientific rationales of combining these new therapeutics and regimens into the multi-modal armamentarium for resectable bone and soft tissue sarcoma.
We welcome submissions of the following subtopics, but not limited to:
1. The efficacy, safety and biomarkers of pre- and post-operative use of novel therapy, such as tyrosine-kinase inhibitor, immunotherapy, etc. in bone and soft tissue sarcoma
2. Individualized, biomarker-guided or pharmacokinetically guided use of novel therapeutic agents based on the investigation of surgical specimens.
3. The potential effect of novel therapeutic agents on the surgical complication and post-surgical outcome of bone and soft tissue sarcoma.
4. Novel multidisciplinary regimens and the use of novel agents in resectable bone and soft tissue sarcoma.
5. Translational research that aims to explore the optimal strategy of surgery in combination with targeted therapy and immunotherapy in bone and soft tissue sarcoma.
In recent years, the field of surgical oncology has witnessed the emerging use of novel therapeutic agents and treatment modalities as front-line regimens for many resectable malignant cancers in the neoadjuvant and adjuvant settings. Such paradigm shift has also been seen in bone and soft tissue sarcoma where novel targeted agents, immunotherapy and multimodal management are now being tested in the peri-operative scenarios. The benefit includes, exposing tumor neoantigen and immune infiltration to therapeutic agents, downstaging a sarcoma into resectable state, and eradicating micro-metastasis to improve survival. However, the optimal candidate, timing, strategy of such peri-operative regimens remains under-studied. The potential increase of peri-operative complication and adverse effect poses new challenges for physicians and surgeons. Therefore, the optimal combination and scientific rationales of these new therapeutics and regimens in the peri-operative setting of bone and soft tissue sarcoma needs to be further investigated.
This Research Topic aims to explore the potential benefit, risk and biomarkers of novel therapeutics and regimens, such as tyrosine-kinase inhibitor, immunotherapy, chemoradiation and intra-tumoral manipulation, in the peri-operative settings for resectable bone and soft tissue sarcoma. Correlative and translational investigation is also welcomed for the optimization of novel combination strategies, patient selection and the scientific rationales of combining these new therapeutics and regimens into the multi-modal armamentarium for resectable bone and soft tissue sarcoma.
We welcome submissions of the following subtopics, but not limited to:
1. The efficacy, safety and biomarkers of pre- and post-operative use of novel therapy, such as tyrosine-kinase inhibitor, immunotherapy, etc. in bone and soft tissue sarcoma
2. Individualized, biomarker-guided or pharmacokinetically guided use of novel therapeutic agents based on the investigation of surgical specimens.
3. The potential effect of novel therapeutic agents on the surgical complication and post-surgical outcome of bone and soft tissue sarcoma.
4. Novel multidisciplinary regimens and the use of novel agents in resectable bone and soft tissue sarcoma.
5. Translational research that aims to explore the optimal strategy of surgery in combination with targeted therapy and immunotherapy in bone and soft tissue sarcoma.